Multicenter, Prospective, Non-interventional Study "Sorafenib as Neoadjuvant Therapy Before Cytoreductive Nephrectomy in Patients With Metastatic Renal Cell Carcinoma"
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 23 Aug 2017
At a glance
- Drugs Sorafenib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms SANE
- Sponsors Bayer
- 18 Aug 2017 Planned End Date changed from 31 May 2017 to 31 Aug 2017.
- 29 Feb 2016 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
- 10 Jul 2015 Planned End Date changed from 1 Mar 2016 to 1 May 2017 as reported by ClinicalTrials.gov record.